- Home
- Editorial
- News
- Practice Guidelines
- Anesthesiology Guidelines
- Cancer Guidelines
- Cardiac Sciences Guidelines
- Critical Care Guidelines
- Dentistry Guidelines
- Dermatology Guidelines
- Diabetes and Endo Guidelines
- Diagnostics Guidelines
- ENT Guidelines
- Featured Practice Guidelines
- Gastroenterology Guidelines
- Geriatrics Guidelines
- Medicine Guidelines
- Nephrology Guidelines
- Neurosciences Guidelines
- Obs and Gynae Guidelines
- Ophthalmology Guidelines
- Orthopaedics Guidelines
- Paediatrics Guidelines
- Psychiatry Guidelines
- Pulmonology Guidelines
- Radiology Guidelines
- Surgery Guidelines
- Urology Guidelines
Beware ! Some medicines for prostate hypertrophy increase risk of Diabetes: BMJ
Certain medicines for prostate hypertrophy increase risk of Diabetes finds a new study.
Some men with benign prostatic hyperplasia (BPH) who are on medical treatment are prescribed 5α-reductase inhibitors for managing their symptoms and avoid symptom of acute urinary retention of urine.Some of the most common of the group are dutasteride or finasteride.
According to an observational study, these men with benign prostatic hyperplasia (BPH), treatment on 5α-reductase inhibitors for controlling their disease have an increased risk for type 2 diabetes.The study has been published in The BMJ.
Previous studies suggest that commonly used drugs, such as antihypertensives, statins,
The researchers conducted the study to investigate the incidence of new onset type 2 diabetes mellitus in men receiving steroid 5α-reductase inhibitors for long term treatment of benign prostatic hyperplasia.
The researchers using a U.K. primary care database, identified over 39,000 patients prescribed 5α-reductase inhibitors and 16,000 prescribed tamsulosin.
In the CPRD, 2081 new onset type 2 diabetes events (368 dutasteride, 1207 finasteride, and 506 tamsulosin) were recorded during a mean follow-up time of 5.2 years (SD 3.1 years
During 5 years' follow-up, the rate of new diabetes diagnosis was roughly 76 per 10,000 person-years with dutasteride or finasteride, compared with 60 per 10,000 with tamsulosin. After multivariable adjustment, each 5α-reductase inhibitor was associated with about a 30% increased risk for diabetes relative to tamsulosin.
The researchers note that previous studies have shown that dutasteride can induce insulin resistance and hepatic steatosis. They concluded that the risk of developing new onset type 2 diabetes appears to be higher in men with benign prostatic hyperplasia exposed to 5α-reductase inhibitors than in men receiving tamsulosin, but did not differ between men receiving dutasteride and those receiving finasteride. Additional monitoring might be required for men starting these drugs, particularly in those with other risk factors for type 2 diabetes.
For further reference log on to:
doi: https://doi.org/10.1136/
benignbenign prostatic hyperplasiaBigBMJBritish Medical JournaldiabetesdihydrotestosteronedutasterideFinasteridehyperplasiahypertrophyincreaseMedicinesProstateretentionrisksomeTamsulosinType 2 Diabetes Mellitus.Urimaxurinaryurine
Next Story
NO DATA FOUND
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd